High Cholesterol In Your 40s Increases Risk Of Alzheimer's Disease
People with high cholesterol in their early 40s are more likely to develop Alzheimer's disease than those with low cholesterol, according to research that will be presented at the upcoming American Academy of Neurology 60th Anniversary Annual Meeting in Chicago, April 12-19, 2008.
Tredaptive Recommended For EU Approval For The Treatment Of Mixed Dyslipidaemia And Primary Hypercholesterolaemia
Merck Sharp & Dohme Limited (MSD) announced that the Committee for Medicinal Products for Human Use (CHMP) has recommended marketing approval for 'Tredaptive'™ (nicotinic acid/laropiprant, MSD) 1000 mg / 20 mg modified-release tablets for the treatment of mixed dyslipidaemia and primary hypercholesterolaemia.
LifeCycle Pharma Announces Positive Data From LCP-AtorFen Phase II Clinical Program
LifeCycle Pharma A/S (OMX:LCP) announced positive results from the company's Phase II clinical program with LCP-AtorFen, a fixed-dose combination product of atorvastatin and fenofibrate for the treatment of mixed dyslipidemia. LCP-AtorFen is a convenient single tablet with a once-daily dosage profile and is without food effect.
Transporting Your Apolipoproteins Testing To The Next Level
Randox produces high quality apolipoprotein tests for the diagnosis, monitoring and research of cardiovascular disease and related conditions. Apolipoproteins are essential components of lipoproteins, for example HDL and LDL, responsible for transporting cholesterol and triglycerides around the body.
New Blood Test Reveals Risk For Metabolic Syndrome
University of Minnesota researchers have discovered that people with high oxidation levels of the low-density lipoprotein (LDL) particle that carries cholesterol throughout the blood are much more likely to develop metabolic syndrome - which can lead to a considerably increased risk of developing heart disease.
Pfizer And Ranbaxy Settle Lipitor Patent Litigation Worldwide
Pfizer Inc announced that it has entered into an agreement with generics manufacturer Ranbaxy Laboratories Ltd. of India and certain of its affiliates to settle substantially all their patent litigation worldwide involving Lipitor, the world's most-prescribed cholesterol-lowering medicine.
Incyte's Selective Oral Inhibitor Of 11beta-HSD1 Demonstrates Improvements In Insulin Sensitivity And Lowers Cholesterol Levels In Type 2 Diabetics
Incyte Corporation (Nasdaq:INCY) announced clinical results presented today at the American Diabetes Association 68th Scientific Sessions of its Phase IIa trial of INCB13739, an orally bioavailable inhibitor of the 11beta-hydroxysteroid dehydrogenase type 1 (11beta-HSD1) enzyme.
Lower Blood Pressure Linked To Statins
An article published in the Archives of Internal Medicinereports that statins - medications that are usually prescribed to lowerblood cholesterol levels - may also lower blood pressure. Beatrice A.Golomb, M.D., Ph.D., (University of California, San Diego, La Jolla)and colleagues noted a modest but significant reduction in bloodpressure for patients taking statins.
Two Merck Medicines Recommended For Approval In The European Union
Merck & Co., Inc. announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has recommended two medicines for marketing approval in the European Union (EU). The CHMP recommended marketing approval for TREDAPTIVE™
PanGenex PGXC Introduces LIPIDEME trade; To Lower Cholesterol Naturally And Increase Cardiovascular Health
PanGenex Corporation (Pink Sheets: PGXC) announces the product launch of LIPIDEME™ , an all-natural nutraceutical formulated with scientifically proven ingredients and the first product on the market to combine the triglyceride-lowering power of Omega-3 fatty acids with the cholesterol lowering ability of phytosterols and tocotrienols - plus the free-radical fighting capacity of Coenzyme Q10 (CoQ10).